Royal Bank of Canada’s Protalix BioTherapeutics PLX Stock Holding History

Royal Bank of Canada’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$16K	Buy	7,568 +4,164	+122%	+$10.3K	﹤0.01%	5991
2025 Q4	$6K	Buy	3,404 +2,331	+217%	+$4.77K	﹤0.01%	6656
2025 Q3	$2K	Buy	1,073 +780	+266%	+$1.27K	﹤0.01%	6903
2025 Q2	$0	Buy	+293	New	+$599	﹤0.01%	7262
2024 Q3	–	Sell	-1,244	Closed	-$1K	–	7290
2024 Q2	$1K	Sell	1,244 -437	-26%	-$516	﹤0.01%	6877
2024 Q1	$2K	Sell	1,681 -20,121	-92%	-$30K	﹤0.01%	6691
2023 Q4	$39K	Buy	21,802 +10,663	+96%	+$16.6K	﹤0.01%	6098
2023 Q3	$18K	Buy	11,139 +4,640	+71%	+$8.33K	﹤0.01%	6215
2023 Q2	$13K	Buy	+6,499	New	+$15.5K	﹤0.01%	6385
2022 Q4	–	Sell	-373	Closed	–	–	7598
2022 Q3	$0	Buy	373 +358	+2,387%	+$396	﹤0.01%	7753
2022 Q2	$0	Hold	15	–	–	﹤0.01%	7633
2022 Q1	$0	Sell	15 -485	-97%	-$444	﹤0.01%	7944
2021 Q4	$0	Hold	500	–	–	﹤0.01%	7836
2021 Q3	$1K	Sell	500 -620	-55%	-$942	﹤0.01%	7493
2021 Q2	$2K	Buy	1,120 +500	+81%	+$1.72K	﹤0.01%	7260
2021 Q1	$3K	Buy	620 +120	+24%	+$559	﹤0.01%	7172
2020 Q4	$2K	Hold	500	–	–	﹤0.01%	6868
2020 Q3	$2K	Sell	500 -110	-18%	-$398	﹤0.01%	6333
2020 Q2	$2K	Sell	610 -51	-8%	-$174	﹤0.01%	6300
2020 Q1	$1K	Hold	661	–	–	﹤0.01%	6475
2019 Q4	$3K	Sell	661 -1	-0.2%	-$2	﹤0.01%	6496
2019 Q3	$1K	Sell	662 -340	-34%	-$1.01K	﹤0.01%	6500
2019 Q2	$5K	Hold	1,002	–	–	﹤0.01%	6318
2019 Q1	$5K	Buy	1,002 +350	+54%	+$1.58K	﹤0.01%	6270
2018 Q4	$2K	Hold	652	–	–	﹤0.01%	6459
2018 Q3	$5K	Buy	652 +100	+18%	+$502	﹤0.01%	6271
2018 Q2	$2K	Hold	552	–	–	﹤0.01%	6265
2018 Q1	$3K	Hold	552	–	–	﹤0.01%	6055
2017 Q4	$3K	Hold	552	–	–	﹤0.01%	6204
2017 Q3	$3K	Hold	552	–	–	﹤0.01%	6521
2017 Q2	$4K	Hold	552	–	–	﹤0.01%	6122
2017 Q1	$8K	Buy	552 +500	+962%	+$4.5K	﹤0.01%	6066
2016 Q4	$0	Sell	52 -110	-68%	-$491	﹤0.01%	6736
2016 Q3	$1K	Sell	162 -263	-62%	-$1.64K	﹤0.01%	6299
2016 Q2	$3K	Buy	425 +84	+25%	+$671	﹤0.01%	6069
2016 Q1	$2K	Sell	341 -248	-42%	-$2.13K	﹤0.01%	6134
2015 Q4	$6K	Buy	589 +500	+562%	+$5.08K	﹤0.01%	6108
2015 Q3	$1K	Sell	89 -1,260	-93%	-$20K	﹤0.01%	6504
2015 Q2	$26K	Sell	1,349 -1,157	-46%	-$24K	﹤0.01%	5572
2015 Q1	$45K	Sell	2,506 -161	-6%	-$3.15K	﹤0.01%	5019
2014 Q4	$49K	Sell	2,667 -3,251	-55%	-$69.8K	﹤0.01%	5074
2014 Q3	$143K	Sell	5,918 -5,339	-47%	-$154K	﹤0.01%	4414
2014 Q2	$411K	Buy	+11,257	New	+$454K	﹤0.01%	3608
2014 Q1	–	Sell	-3,170	Closed	-$123K	–	6089
2013 Q4	$123K	Sell	3,170 -2,791	-47%	-$118K	﹤0.01%	4464
2013 Q3	$270K	Buy	5,961 +5,177	+660%	+$266K	﹤0.01%	3868
2013 Q2	$39K	Buy	+784	New	+$41.6K	﹤0.01%	4784

Other funds holding PLX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MCO

MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SWP

Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

PFS

Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Royal Bank of Canada's PLX Position: Q1 2026 in Review

Royal Bank of Canada increased its Protalix BioTherapeutics (PLX) stake by 122% in Q1 2026, buying an estimated $10.3K and bringing the position to 7,568 shares worth $16K. The position accounts for ﹤0.01% of the portfolio, ranked #5991.

Royal Bank of Canada first reported a position in PLX in Q2 2013 and has held it in 46 quarters since. The position peaked at $411K in Q2 2014. 100 funds tracked by Wall St. Rank hold PLX as of Q1 2026.

Royal Bank of Canada held 7,568 shares of Protalix BioTherapeutics worth $16K as of Q1 2026.
Royal Bank of Canada bought 4,164 Protalix BioTherapeutics shares in Q1 2026, an estimated $10.3K.
Protalix BioTherapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #5991 holding.
Royal Bank of Canada first reported a position in Protalix BioTherapeutics in Q2 2013 and has held it in 46 quarters since.
Royal Bank of Canada's Protalix BioTherapeutics position peaked at $411K in Q2 2014.
100 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.